February 22, 2021
Dr. Kartik Chandran is a professor of microbiology and immunology and the Harold and Muriel Block Scholar in Virology at Albert Einstein College of Medicine in New York City, where he oversees a team of researchers engaged in basic and translational research on emerging RNA viruses and investigating the molecular mechanisms of infection.
Dr. Chandran’s laboratory focuses on coronaviruses and filoviruses, including SARS-CoV-2, Ebola virus, and Marburg virus, and other neglected emerging viruses such as hantaviruses and Crimean-Congo hemorrhagic fever virus, and leads a multi-institutional collaboration to discover and develop potent, long-lasting antibody treatments against these viruses.
Dr. Chandran received his Ph.D. in Biochemistry at the University of Wisconsin-Madison, followed by research fellowships at Harvard Medical School and Brigham and Women’s Hospital prior to joining Einstein.
“We are pleased to welcome Dr. Chandran to our Scientific Advisory Board. As a leading virologist and immunologist, he will provide valuable insight as we work to advance our haptenized viral vaccine platform in targeting life-threatening viral diseases,” commented Ken Kovan, President and Chief Operating Officer of BioVaxys Technology Corp. Kovan added, “We also share common interest in exploring synthetic antigens, either to address multiple SARS-CoV-2 variants or as part of a vaccine technology to elicit a stronger immune response for other viruses.”
Dr. Chandran stated, “I look forward to assisting Biovaxys in its efforts to develop new vaccines that will prepare us for future viral outbreaks.” BioVaxys has developed its vaccine technology platforms based on the established immunological concept that modifying proteins with simple chemicals called haptens makes them more visible to the immune system. The process of haptenization “teaches” a patient’s immune system to recognize and make target proteins more ‘visible’ as foreign, thereby stimulating an immune response.